• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

垂体瘤中五种人类生长抑素受体(hSSTR1 - 5)的mRNA表达

Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.

作者信息

Panetta R, Patel Y C

机构信息

Fraser Laboratories, Department of Medicine, McGill University, Royal Victoria Hospital, Montreal, Quebec, Canada.

出版信息

Life Sci. 1995;56(5):333-42. doi: 10.1016/0024-3205(94)00956-2.

DOI:10.1016/0024-3205(94)00956-2
PMID:7530798
Abstract

Expression of mRNA for hSSTR1-5 was determined in secretory (GH, PRL, TSH, ACTH) and nonsecretory pituitary tumors, as well as normal human fetal and adult pituitary by reverse transcriptase (RT) PCR followed by Southern blots. All 5 hSSTR subtype mRNAs were expressed in fetal pituitary, while adult pituitary was positive for 4 subtypes, lacking hSSTR4 mRNA. All 15 tumors analyzed were positive for SSTR mRNA, 14 expressing more than one subtype. SSTR2 mRNA in all tissues was expressed as the 2A variant, there being no detectable transcript for SSTR2B. Amongst the 5 SSTRs, mRNA for SSTR2A was the most frequently expressed (87% of tumors) followed by SSTR1 (73%), SSTR3 (53%), SSTR5 (47%), and SSTR4 (40%). The frequency and pattern of expression of the SSTR mRNAs was virtually identical in the different tumor subclasses and did not correlate with tumor size. Since pituitary tumors are monoclonal in origin, multiple SSTR genes are expressed in individual cells. Most tumors are rich in SSTR1 and SSTR2A mRNA compared to the other subtypes. This implies that SST analogs like SMS 201-995, known to interact with SSTR2A, but not with SSTR1, act on pituitary tumors mainly via the SSTR2 subtype.

摘要

采用逆转录(RT)PCR 随后进行 Southern 印迹法,测定了人 SSTR1 - 5 的 mRNA 在分泌性(生长激素、催乳素、促甲状腺激素、促肾上腺皮质激素)和非分泌性垂体肿瘤以及正常人类胎儿和成人垂体中的表达情况。所有 5 种 hSSTR 亚型的 mRNA 在胎儿垂体中均有表达,而成人垂体中 4 种亚型呈阳性,缺乏 hSSTR4 mRNA。所分析的 15 个肿瘤中 SSTR mRNA 均呈阳性,14 个表达一种以上亚型。所有组织中的 SSTR2 mRNA 均以 2A 变体形式表达,未检测到 SSTR2B 的转录本。在 5 种 SSTR 中,SSTR2A 的 mRNA 表达最为频繁(87%的肿瘤),其次是 SSTR1(73%)、SSTR3(53%)、SSTR5(47%)和 SSTR4(40%)。SSTR mRNA 的表达频率和模式在不同肿瘤亚类中几乎相同,且与肿瘤大小无关。由于垂体肿瘤起源于单克隆,多个 SSTR 基因在单个细胞中表达。与其他亚型相比,大多数肿瘤富含 SSTR1 和 SSTR2A mRNA。这意味着像 SMS 201 - 995 这样已知与 SSTR2A 相互作用但不与 SSTR1 相互作用的生长抑素类似物,主要通过 SSTR2 亚型作用于垂体肿瘤。

相似文献

1
Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.垂体瘤中五种人类生长抑素受体(hSSTR1 - 5)的mRNA表达
Life Sci. 1995;56(5):333-42. doi: 10.1016/0024-3205(94)00956-2.
2
Somatostatin receptor subtype gene expression in pituitary adenomas.垂体腺瘤中生长抑素受体亚型基因表达
J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92. doi: 10.1210/jcem.80.4.7714115.
3
Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.促甲状腺素分泌型垂体腺瘤中生长抑素受体亚型mRNA:一例显示短期奥曲肽治疗期间肿瘤大小显著缩小的病例
Endocr J. 2007 Jun;54(3):371-8. doi: 10.1507/endocrj.k06-177. Epub 2007 Apr 10.
4
Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.垂体腺瘤中生长抑素受体(SSTR)亚型的表达:通过逆转录-聚合酶链反应对SSTR2 mRNA进行定量分析。
J Neuroendocrinol. 1996 Aug;8(8):605-10.
5
Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.生长抑素受体亚型的鉴定及其对生长抑素类似物SMS 201-995治疗人类内分泌肿瘤疗效的影响。
J Clin Invest. 1994 Mar;93(3):1321-5. doi: 10.1172/JCI117090.
6
Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.生长激素瘤和无功能垂体腺瘤中生长抑素受体亚型(SSTR1 - 5)基因表达水平的定量分析。
Eur J Endocrinol. 2007 Jan;156(1):65-74. doi: 10.1530/eje.1.02313.
7
Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.垂体腺瘤中三种生长抑素受体亚型的表达:乳腺生长激素细胞谱系中优先表达SSTR5的证据。
J Clin Endocrinol Metab. 1994 Sep;79(3):724-9. doi: 10.1210/jcem.79.3.7521350.
8
Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.垂体瘤中两种生长抑素受体亚型的异质性表达。
J Clin Endocrinol Metab. 1994 Feb;78(2):398-403. doi: 10.1210/jcem.78.2.8106629.
9
Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.生长抑素受体1亚型在分泌人生长激素(GH)和催乳素(PRL)的垂体腺瘤中的选择性激活:对细胞活力、GH和PRL分泌的影响。
J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802. doi: 10.1210/jc.2002-021825.
10
Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis.生长抑素受体(sstr)2型和5型mRNA在大鼠垂体单个细胞中的表达。双重标记原位杂交分析。
Endocrinology. 1995 Nov;136(11):5232-5. doi: 10.1210/endo.136.11.7588263.

引用本文的文献

1
Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.生长抑素的激动剂、拮抗剂与受体:在肿瘤中的病理生理学及治疗意义
Curr Issues Mol Biol. 2024 Sep 2;46(9):9721-9759. doi: 10.3390/cimb46090578.
2
The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary.肽受体放射性核素治疗对肿瘤性及正常垂体的影响
Cancers (Basel). 2023 May 11;15(10):2710. doi: 10.3390/cancers15102710.
3
[68 Ga]-DOTATATE PET/MR-based evaluation of physiologic somatostatin receptor 2 expression in the adult pituitary gland as a function of age and sex in a prospective cohort.
[68Ga]-DOTATATE PET/MR 基于前瞻性队列研究评估成人垂体中生长抑素受体 2 的生理表达与年龄和性别之间的关系。
Pituitary. 2023 Aug;26(4):419-428. doi: 10.1007/s11102-023-01329-0. Epub 2023 Jun 7.
4
Reassessment of SST4 Somatostatin Receptor Expression Using SST4-eGFP Knockin Mice and the Novel Rabbit Monoclonal Anti-Human SST4 Antibody 7H49L61.使用 SST4-eGFP 基因敲入小鼠和新型兔单克隆抗人 SST4 抗体 7H49L61 重新评估 SST4 生长抑素受体表达。
Int J Mol Sci. 2021 Nov 30;22(23):12981. doi: 10.3390/ijms222312981.
5
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours.肽受体放射性核素治疗神经内分泌肿瘤后的垂体功能。
Cancer Med. 2021 Dec;10(23):8405-8411. doi: 10.1002/cam4.4345. Epub 2021 Oct 26.
6
Somatostatin Analogs in Clinical Practice: a Review.生长抑素类似物在临床实践中的应用:综述。
Int J Mol Sci. 2020 Feb 29;21(5):1682. doi: 10.3390/ijms21051682.
7
Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells.表观遗传途径抑制剂对促肾上腺皮质细胞瘤 AtT20 细胞的影响。
Endocr Relat Cancer. 2020 Mar;27(3):163-174. doi: 10.1530/ERC-19-0448.
8
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.国际基础和临床药理学联合会。生长抑素受体:结构、功能、配体和新命名。
Pharmacol Rev. 2018 Oct;70(4):763-835. doi: 10.1124/pr.117.015388.
9
Novel Somatostatin Receptor Ligands Therapies for Acromegaly.用于肢端肥大症的新型生长抑素受体配体疗法
Front Endocrinol (Lausanne). 2018 Mar 7;9:78. doi: 10.3389/fendo.2018.00078. eCollection 2018.
10
Evans Blue Attachment Enhances Somatostatin Receptor Subtype-2 Imaging and Radiotherapy.埃文斯蓝缀合物增强生长抑素受体亚型 2 成像和放射治疗。
Theranostics. 2018 Jan 1;8(3):735-745. doi: 10.7150/thno.23491. eCollection 2018.